Fate Therapeutics - William Rastetter becomes Chairmen & Interim CEO
Monday, December 19, 2011 at 10:58AM
DDE Editor in Stem Cell Research, fate, idec

William Rastetter PhD is best known for his time at Idec Pharmaceuticals (can you say rituxan). He is considered a heavyweight in the biotechnology world so his willingness to take on this role at Fate Therapeutics is not only positive for Fate but for the industry overall. Fate Therapeutics is working on ProHema (umbilical cord blood transplants (UCB), with data recently presented at ASH.

Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.